一次電池の世界市場予測(〜2025):オリジン別(ヒト一次電池、動物一次電池)、種類別(造血、皮膚細胞、胃腸、肝細胞、肺、腎、筋骨格、心臓)、エンドユーザー別、地域別

◆英語タイトル:Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region - Global Forecast to 2025
◆商品コード:BT 6489
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年10月20日
◆ページ数:176
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は一次電池の世界市場が2020年970百万ドルから2025年1613百万ドルまで、年平均10.7%成長すると展望しています。本調査レポートでは、一次電池の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、オリジン別(ヒト一次電池、動物一次電池)分析、種類別(造血細胞、皮膚細胞、胃腸細胞、肝細胞、肺細胞)分析、用途別(MEMS、CIS、メモリー、RFデバイス、LED)分析、エンドユーザー別(生命科学研究会社、研究所)分析、地域別分析、競争状況、企業評価・情報など、以下の構成でお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・一次電池の世界市場規模:オリジン別(ヒト一次電池、動物一次電池)
・一次電池の世界市場規模:種類別(造血細胞、皮膚細胞、胃腸細胞、肝細胞、肺細胞)
・一次電池の世界市場規模:用途別(MEMS、CIS、メモリー、RFデバイス、LED)
・一次電池の世界市場規模:エンドユーザー別(生命科学研究会社、研究所)
・一次電池の世界市場規模:地域別
・競争状況
・企業評価・情報
【レポートの概要】

“The global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7% during the forecast period.” Market growth is driven by the rising prevalence of cancer, the rapid growth in the biotechnology & biopharmaceutical industries, growing focus on R&D, recent developments in stem cell therapy, the increasing demand for monoclonal antibodies, and advantages of primary human cells over cell lines are the major factors driving the growth of the primary cells market.

“The human primary cells accounted for the highest growth rate in the primary cells market, by origin, during the forecast period”
Based on origin, the primary cells market is segmented into human and animal primary cells. The human primary cells segment accounted for the highest growth rate in the primary cells market in 2019. The increasing funding for the R&D of regenerative therapies, the rising incidence of cancer, and the growing application areas of human stem cells are the major factors driving the growth of this segment.

“Hepatocytes segment accounted for the highest CAGR”
Based on type, the primary cells market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2019, the hepatocytes segment accounted for the highest growth rate. Increasing research funding by key pharma players, increasing incidence of liver cancer & pediatric liver diseases across the globe, and the emergence of new companies dedicated to liver therapeutics research are the major factors driving the growth of this segment.

“Life science research companies segment accounted for the highest CAGR”
Based on end-users, the primary cells market is segmented into life science research companies and research institutes. In 2019, the life science research companies segment accounted for the highest growth rate. This can be attributed to the increasing investments of companies in cell-based research, high adoption of primary cells in cell-based experiments, increasing cancer research in life science research companies, and the increasing number of R&D facilities globally.

“Asia Pacific: The fastest-growing region primary cells market”
The global primary cells market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in this region can be attributed to the increasing research activities in Asian countries, the availability of funding for research, a growing number of biobanks & research centers, rising prevalence of cancer, and recent developments in tissue engineering & stem cell therapy.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, and Rest of the World – 12%

Lits of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Lonza (Switzerland)
• Cell Biologics, Inc. (US)
• PromoCell GmbH (Germany)
• HemaCare Corporation (US)
• ZenBio, Inc. (US)
• STEMCELL Technologies, Inc. (Canada)
• Corning Incorporated (US)
• AllCells (US)
• American Type Culture Collection (US)
• Axol Bioscience Ltd. (UK)
• iXCells Biotechnologies (US)
• Neuromics (US)
• StemExpress (US)
• BioIVT (US)
• ScienCell Research Laboratories, Inc. (US)
• PPA Research Group, Inc. (US)
• Creative Bioarray (US)
• BPS Bioscience, Inc. (US)
• Epithelix Sàrl (Switzerland)
• ReachBio LLC (US)
• AcceGen (US)
• Sekisui XenoTech, LLC (US)
• Biopredic International (France).

Research Coverage:
This report provides a detailed picture of the global primary cells market. It aims at estimating the size and future growth potential of the market across different segments, such as origin, type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall primary cells market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, and opportunities.

【レポートの目次】

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.2.1 INCLUSIONS & EXCLUSIONS 20
1.2.2 MARKETS COVERED 20
FIGURE 1 PRIMARY CELLS MARKET 20
1.2.3 YEARS CONSIDERED FOR THE STUDY 21
1.3 CURRENCY 21
1.4 LIMITATIONS 21
1.5 STAKEHOLDERS 21
1.6 REPORT COMPARISON WITH THE JULY 2018 EDITION 22
1.6.1 SUMMARY OF CHANGES 22
1.6.2 LIMITATIONS OF THE CURRENT EDITION 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.2 RESEARCH APPROACH 23
FIGURE 2 PRIMARY CELLS MARKET: RESEARCH DESIGN 23
2.2.1 SECONDARY DATA 24
2.2.1.1 Key data from secondary sources 24
2.2.2 PRIMARY DATA 25
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
2.2.2.1 Key data from primary sources 26
2.3 MARKET SIZE ESTIMATION 26
2.3.1 BOTTOM-UP APPROACH 27
FIGURE 4 PRIMARY CELLS MARKET: BOTTOM-UP APPROACH 27
2.3.2 TOP-DOWN APPROACH 28
FIGURE 5 PRIMARY CELLS MARKET: TOP-DOWN APPROACH 28
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 29
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
2.5 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
FIGURE 7 PRIMARY CELLS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION) 31
FIGURE 8 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION) 32
FIGURE 9 PRIMARY CELLS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION) 32
FIGURE 10 PRIMARY CELLS MARKET, BY REGION, 2020 VS. 2025 (USD MILLION) 33

4 PREMIUM INSIGHTS 34
4.1 PRIMARY CELLS MARKET OVERVIEW 34
FIGURE 11 INCREASING CANCER RESEARCH IS DRIVING THE GROWTH OF THE PRIMARY CELLS MARKET 34
4.2 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION) 35
FIGURE 12 HUMAN PRIMARY CELLS SEGMENT TO DOMINATE THE MARKET IN 2020 35
4.3 PRIMARY CELLS MARKET SHARE, BY END USER, 2020 VS. 2025 (USD MILLION) 35
FIGURE 13 LIFE SCIENCE RESEARCH COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD 35
4.4 PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 36
FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
FIGURE 15 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 37
5.2.1 DRIVERS 37
5.2.1.1 Increasing cancer research 37
TABLE 1 PROJECTED INCREASE IN THE NUMBER OF CANCER PATIENTS,
2015 VS. 2018 VS. 2035 38
TABLE 2 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE,
2015 VS. 2017 (USD MILLION) 38
5.2.1.2 Advantages of primary human cells over cell lines 39
5.2.1.3 Increasing demand for monoclonal antibodies 39
5.2.1.4 Rapid growth in the biotechnology and biopharmaceutical industries 39
FIGURE 16 GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL
R&D EXPENDITURE, 2017–2024 40
5.2.1.5 Growing focus on personalized medicine 40
TABLE 3 GROWTH IN THE NUMBER OF PERSONALIZED MEDICATIONS, 2008–2016 40
5.2.1.6 Government investments for cell-based research 41
5.2.2 RESTRAINTS 42
5.2.2.1 Concerns regarding primary cell culture contamination 42
5.2.2.2 Ethical concerns regarding research in cell biology 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 Advancing biomedical research using primary cells in 3D cultures 42
5.3 COVID-19 IMPACT ON THE PRIMARY CELLS MARKET 43
5.4 PRICING ANALYSIS 44
TABLE 4 PRICE OF PRIMARY CELLS (2020) 44
5.5 VALUE CHAIN ANALYSIS 46
FIGURE 17 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 47
5.6 SUPPLY CHAIN ANALYSIS 47
FIGURE 18 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 48
5.7 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET 49
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET 49
6 PRIMARY CELLS MARKET, BY ORIGIN 50
6.1 INTRODUCTION 51
TABLE 5 PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 51
6.2 HUMAN PRIMARY CELLS 51
6.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH 51
TABLE 6 HUMAN PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 52
6.3 ANIMAL PRIMARY CELLS 53
6.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL
THE MARKET GROWTH 53
TABLE 7 ANIMAL PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 53
7 PRIMARY CELLS MARKET, BY TYPE 54
7.1 INTRODUCTION 55
TABLE 8 PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 55
7.2 HEMATOPOIETIC CELLS 56
7.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL
THE MARKET GROWTH 56
TABLE 9 HEMATOPOIETIC CELLS, BY TYPE 56
TABLE 10 HEMATOPOIETIC CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 57
TABLE 11 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 57
TABLE 12 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 57
TABLE 13 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 58
7.3 DERMATOCYTES 58
7.3.1 RISING PREVALENCE OF MELANOMA IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT 58
TABLE 14 DERMATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 59
TABLE 15 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 16 EUROPE: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 59
TABLE 17 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 60
7.4 GASTROINTESTINAL CELLS 60
7.4.1 INCREASING INCIDENCE OF STOMACH CANCER TO BOLSTER MARKET GROWTH 60
TABLE 18 GASTROINTESTINAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 60
TABLE 19 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 20 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 61
TABLE 21 ASIA PACIFIC: PRIMARY GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 61
7.5 HEPATOCYTES 62
TABLE 22 GLOBAL LIVER DISORDER INCIDENCE 62
TABLE 23 HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 63
TABLE 24 HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 63
TABLE 25 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 64
TABLE 26 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 64
TABLE 27 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 64
7.5.1 CRYOPRESERVED HEPATOCYTES 65
7.5.1.1 Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth 65
TABLE 28 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION,
2018–2025 (USD MILLION) 65
7.5.2 FRESH HEPATOCYTES 65
7.5.2.1 Stringent regulations and limited availability of fresh hepatocytes to limit market growth 65
TABLE 29 FRESH HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION) 66
7.6 LUNG CELLS 66
7.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE THE DEMAND FOR LUNG CELLS 66
TABLE 30 LUNG CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 31 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 67
TABLE 32 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 68
TABLE 33 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 68
7.7 RENAL CELLS 68
7.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO
PROPEL MARKET GROWTH 68
TABLE 34 RENAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 69
TABLE 35 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 69
TABLE 36 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 69
TABLE 37 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 70
7.8 HEART CELLS 70
7.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES IS SUPPORTING THE GROWTH OF THIS SEGMENT 70
TABLE 38 HEART CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 70
TABLE 39 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
TABLE 40 EUROPE: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
TABLE 41 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
7.9 MUSCULOSKELETAL CELLS 72
7.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH 72
TABLE 42 MUSCULOSKELETAL CELLS MARKET, BY REGION,
2018–2025 (USD MILLION) 72
TABLE 43 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 72
TABLE 44 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 73
TABLE 45 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 73
7.10 OTHER PRIMARY CELLS 73
TABLE 46 OTHER PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 74
TABLE 47 NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 74
TABLE 48 EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 74
TABLE 49 ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 75
8 PRIMARY CELLS MARKET, BY END USER 76
8.1 INTRODUCTION 77
TABLE 50 PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 77
8.2 LIFE SCIENCE RESEARCH COMPANIES 77
8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE THE MARKET GROWTH 77
TABLE 51 PRIMARY CELLS MARKET FOR LIFE SCIENCE RESEARCH COMPANIES,
BY REGION, 2018–2025 (USD MILLION) 78
8.3 RESEARCH INSTITUTES 78
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER ARE DRIVING MARKET GROWTH 78
TABLE 52 PRIMARY CELLS MARKET FOR RESEARCH INSTITUTES, BY REGION,
2018–2025 (USD MILLION) 79
9 PRIMARY CELLS MARKET, BY REGION 80
9.1 INTRODUCTION 81
TABLE 53 PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION) 81
9.2 NORTH AMERICA 81
FIGURE 20 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 82
FIGURE 21 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT 83
TABLE 54 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 55 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN,
2018–2025 (USD MILLION) 84
TABLE 56 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE,
2018–2025 (USD MILLION) 84
TABLE 57 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE,
2018–2025 (USD MILLION) 85
TABLE 58 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 85
9.2.1 US 85
9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth in the US 85
FIGURE 22 US: CANCER INCIDENCE & MORTALITY, 2012–2035 86
TABLE 59 US: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 86
TABLE 60 US: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 87
TABLE 61 US: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 87
TABLE 62 US: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 87
9.2.2 CANADA 88
9.2.2.1 Presence of advanced R&D infrastructure to drive market growth 88
TABLE 63 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 88
TABLE 64 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 65 CANADA: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 89
9.3 EUROPE 89
FIGURE 23 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 90
TABLE 66 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 90
TABLE 67 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 90
TABLE 68 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 69 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 70 EUROPE: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 91
9.3.1 UK 92
9.3.1.1 Growth in the life sciences industry to drive market growth in the UK 92
TABLE 71 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 92
TABLE 72 UK: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 73 UK: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 93
9.3.2 GERMANY 93
9.3.2.1 Increasing life science research activities to support market growth 93
TABLE 74 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN,
2018–2025 (USD MILLION) 94
TABLE 75 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 76 GERMANY: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 95
9.3.3 FRANCE 95
9.3.3.1 Robust biotechnology infrastructure in the country to support market growth 95
TABLE 77 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 95
TABLE 78 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 79 FRANCE: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 96
9.3.4 ITALY 96
9.3.4.1 Increasing number of cell biology seminars and conferences to fuel the adoption of primary cells 96
TABLE 80 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 97
TABLE 81 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 82 ITALY: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 98
9.3.5 REST OF EUROPE 98
TABLE 83 ROE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 98
TABLE 84 ROE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 85 ROE: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 99
9.4 ASIA PACIFIC 100
FIGURE 24 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 100
FIGURE 25 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT 101
TABLE 86 APAC: PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 102
TABLE 87 APAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 102
TABLE 88 APAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 89 APAC: HEPATOCYTES, BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 90 APAC: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 103
9.4.1 CHINA 103
9.4.1.1 Growing focus on cancer therapeutics-related research to bolster market growth 103
TABLE 91 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 104
TABLE 92 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 93 CHINA: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 105
9.4.2 JAPAN 105
9.4.2.1 Government initiatives to propel market growth in Japan 105
TABLE 94 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 105
TABLE 95 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 96 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 106
9.4.3 REST OF ASIA PACIFIC 106
TABLE 97 ROAPAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 107
TABLE 98 ROAPAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 99 ROAPAC: PRIMARY CELLS MARKET, BY END USER,
2018–2025 (USD MILLION) 107
9.5 REST OF THE WORLD 108
TABLE 100 ROW: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION) 108
TABLE 101 ROW: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 102 ROW: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 103 ROW: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION) 109
10 COMPETITIVE LANDSCAPE 110
10.1 OVERVIEW 110
FIGURE 26 KEY DEVELOPMENTS IN THE PRIMARY CELLS MARKET (2017 TO 2020) 110
10.2 MARKET SHARE ANALYSIS 111
FIGURE 27 PRIMARY CELLS MARKET SHARE, BY KEY PLAYER (2019) 111
10.3 COMPETITIVE SCENARIO 112
10.3.1 PRODUCT LAUNCHES 112
TABLE 104 PRODUCT LAUNCHES 112
10.3.2 AGREEMENTS 113
TABLE 105 AGREEMENTS 113
10.3.3 EXPANSIONS 113
TABLE 106 EXPANSIONS 113
10.3.4 PARTNERSHIPS 114
TABLE 107 PARTNERSHIPS 114
10.3.5 ACQUISITIONS 115
TABLE 108 ACQUISITIONS 115
11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 116
11.1 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY 116
11.1.1 VENDOR EXCLUSION CRITERIA 116
11.1.2 STARS 116
11.1.3 EMERGING LEADERS 116
11.1.4 PERVASIVE PLAYERS 116
11.1.5 PARTICIPANTS 116
FIGURE 28 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 117
11.2 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019) 117
11.2.1 PROGRESSIVE COMPANIES 117
11.2.2 STARTING BLOCKS 118
11.2.3 RESPONSIVE COMPANIES 118
11.2.4 DYNAMIC COMPANIES 118
FIGURE 29 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019 118
11.3 COMPANY PROFILES 119
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.3.1 THERMO FISHER SCIENTIFIC, INC. 119
FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 119
11.3.2 MERCK KGAA 122
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2019) 122
11.3.3 LONZA 127
FIGURE 32 LONZA: COMPANY SNAPSHOT (2019) 127
11.3.4 PROMOCELL GMBH 130
11.3.5 CORNING INCORPORATED 132
FIGURE 33 CORNING INCORPORATED: COMPANY SNAPSHOT (2019) 132
11.3.6 AMERICAN TYPE CULTURE COLLECTION (ATCC) 134
11.3.7 CELL BIOLOGICS, INC. 136
11.3.8 HEMACARE CORPORATION (A CHARLES RIVER LABORATORIES, INC. COMPANY) 140
FIGURE 34 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2019) 140
11.3.9 ZENBIO, INC. 143
11.3.10 STEM CELL TECHNOLOGIES, INC. 144
11.3.11 ALLCELLS 146
11.3.12 AXOL BIOSCIENCE LTD. 147
11.3.13 IXCELLS BIOTECHNOLOGIES 150
11.3.14 NEUROMICS 155
11.3.15 STEMEXPRESS 157
11.3.16 BIOIVT 159
11.3.17 SCIENCELL RESEARCH LABORATORIES, INC. 163
11.3.18 SEKISUI XENOTECH, LLC 165
11.3.19 PPA RESEARCH GROUP, INC. 167
11.3.20 CREATIVE BIOARRAY 168
11.3.21 BPS BIOSCIENCE, INC. 170
11.3.22 EPITHELIX SÀRL 170
11.3.23 REACHBIO LLC 171
11.3.24 ACCEGEN 171
11.3.25 BIOPREDIC INTERNATIONAL 172
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 173
12.1 INSIGHTS FROM INDUSTRY EXPERTS 173
12.2 DISCUSSION GUIDE 174
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 176
12.4 AVAILABLE CUSTOMIZATIONS 178
12.5 RELATED REPORTS 178
12.6 AUTHOR DETAILS 179



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[一次電池の世界市場予測(〜2025):オリジン別(ヒト一次電池、動物一次電池)、種類別(造血、皮膚細胞、胃腸、肝細胞、肺、腎、筋骨格、心臓)、エンドユーザー別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆